Form 4: Emergent BioSolutions EVP Richard Lindahl Reports Stock and Options Transactions

EVP and CFO Richard Lindahl reports acquisition of restricted stock units and employee stock options in Emergent BioSolutions.

Summary

• Richard S. Lindahl, EVP and Chief Financial Officer of Emergent BioSolutions Inc., filed a Form 4.
• The filing reports the acquisition of 146,888 shares of common stock through restricted stock units on March 6, 2025.
• These restricted stock units vest in three annual installments.
• Lindahl also acquired 178,546 employee stock options with an exercise price of $5.80 on March 6, 2025, which vest in three equal installments and expire on March 5, 2032.
• Following these transactions, Lindahl beneficially owns 299,225 shares of common stock and 484,490 derivative securities.

Sentiment

Score: 6

Explanation: Neutral sentiment as it's a standard disclosure of stock and option grants. The grants themselves suggest a positive outlook from the company regarding executive retention and performance incentives.

Positives

• The acquisition of restricted stock units and stock options by a key executive signals confidence in the company's future performance.

Industry Context

Form 4 filings are routine disclosures required by the SEC to provide transparency into the transactions of company insiders, allowing investors to track executive sentiment and potential alignment with shareholder interests.

Stakeholder Impact

• The transactions may have a minor positive impact on shareholder sentiment due to the alignment of executive interests with company performance.

Key Dates